{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:11:56Z","timestamp":1761559916342},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"vor","delay-in-days":821,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,4]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Drug therapy for Crohn\u2019s disease and ulcerative colitis is based on anti\u2010inflammatory and immunodulating drugs, nutritional support and surgical resection. Recently, new drugs have been introduced.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To report drug prescriptions, costs and adverse reactions among inflammatory bowel disease patients in Sweden between 1988 and 1997.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Drug use was calculated from the national Diagnosis and therapy survey and drug costs from prescriptions and drug sales. Adverse drug reactions were obtained from the Medical Products Agency\u2019s National Pharmacovigilance system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The annual drug exposure for Crohn\u2019s disease was 0.55 million daily doses per million population, mainly supplementation and aminosalicylic acids. Mesalazine and olsalazine had 61% within this group. For ulcerative colitis patients, drug exposure was 0.61 million daily doses per million per year and aminosalicylic acids fell from 70% to 65%. For inflammatory bowel disease patients, corticosteroids and nutritional supplementation were common. The annual average cost for inflammatory bowel disease drugs was 7.0\u2003million US dollars. Anually, 32 adverse drug reactions were reported, mainly haematological reactions such as agranulocytosis and pancytopenia (60%), followed by skin reactions. Only two deaths were reported. Aminosalicylic acids were the most commonly reported compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Drug use for inflammatory bowel disease in the pre\u2010biologic agent era rested on aminosalicylic acid drugs and corticosteroids with stable levels, proportions and costs. The level of adverse drug reactions was low but haematological reactions support the monitoring of inflammatory bowel disease patients.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.00942.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:44:03Z","timestamp":1047354243000},"page":"475-481","source":"Crossref","is-referenced-by-count":28,"title":["A 10\u2010year survey of inflammatory bowel diseases\u2014drug therapy, costs and adverse reactions"],"prefix":"10.1111","volume":"15","author":[{"given":"P.","family":"Blomqvist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Feltelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"L\u00f6fberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ekbom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609006411"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529209000168"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709002993"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603283341307"},{"key":"e_1_2_6_6_2","first-page":"12S","article-title":"Optimizing therapy for inflammatory bowel disease","volume":"92","author":"Robinson M","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1997.86883000.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855040-00004"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00511.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/09629359891045"},{"key":"e_1_2_6_11_2","first-page":"816","article-title":"5\u2010Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis","volume":"92","author":"Walker AM","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_12_2","first-page":"108","article-title":"Double\u2010blind comparative study of sulfasalazine and controlled\u2010release mesalazine tablets in the treatment of active ulcerative colitis","volume":"30","author":"Munakata A","year":"1995","journal-title":"J Gastroenterol"},{"key":"e_1_2_6_13_2","first-page":"115","article-title":"Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine","volume":"30","author":"Nakajima H","year":"1995","journal-title":"J Gastroenterol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.4.313"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1992.tb00544.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8652(199803)57:3<206::aid-ajh4>3.0.co;2-z"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311304"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199106030-00005"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0016-5085(79)90386-X","article-title":"National Cooperative Crohn\u2019s Disease Study: adverse reactions to study drugs","volume":"77","author":"Singleton JW","year":"1979","journal-title":"Gastroenterology"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007523"},{"key":"e_1_2_6_21_2","unstructured":"Statistical Yearbook 1997. Stockholm: The National Corporation of Swedish Pharmacies 1998."},{"key":"e_1_2_6_22_2","unstructured":"Statistical Yearbook of Sweden 2000 Vol. 86 Statistics Sweden 2000."},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","unstructured":"WiholmBE.Postmarketing surveillance of ADRs by spontaneous reporting and register data: The Swedish approach. In: Strom BL Velo G eds. Drug Epidemiology and Post\u2010Marketing Surveillance. New York: Plenum Press 1992: 9\u201320.","DOI":"10.1007\/978-1-4899-2587-9_2"},{"key":"e_1_2_6_24_2","first-page":"1171","article-title":"Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions","volume":"27","author":"Blomqvist P","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050498"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.05417.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00881.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00942.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00942.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.00942.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:33:27Z","timestamp":1697506407000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.00942.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["10.1046\/j.1365-2036.2001.00942.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00942.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4]]}}}